Plus Therapeutics (PSTV) Cash from Operations (2016 - 2025)
Plus Therapeutics has reported Cash from Operations over the past 16 years, most recently at 6275000.0 for Q4 2025.
- Quarterly Cash from Operations fell 418.17% to 6275000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 20775000.0 through Dec 2025, down 96.84% year-over-year, with the annual reading at 20775000.0 for FY2025, 96.84% down from the prior year.
- Cash from Operations was 6275000.0 for Q4 2025 at Plus Therapeutics, down from 2530000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1150000.0 in Q2 2024 and troughed at 6275000.0 in Q4 2025.
- The 5-year median for Cash from Operations is 3006000.0 (2021), against an average of 3538705.88.
- Year-over-year, Cash from Operations surged 58.6% in 2024 and then crashed 418.17% in 2025.
- A 5-year view of Cash from Operations shows it stood at 3006000.0 in 2021, then rose by 25.68% to 2234000.0 in 2022, then rose by 15.8% to 1881000.0 in 2023, then skyrocketed by 35.62% to 1211000.0 in 2024, then crashed by 418.17% to 6275000.0 in 2025.
- Per Business Quant, the three most recent readings for PSTV's Cash from Operations are 6275000.0 (Q4 2025), 2530000.0 (Q3 2025), and 5798000.0 (Q2 2025).